Sonnet BioTherapeutics releases 'What This Means' investor segment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 11 2025
0mins
Clinical Trial Update: Sonnet BioTherapeutics announced the completion of enrollment for the SB221 clinical trial's expansion group, with two patients showing partial responses in the E6 dose escalation cohort, and plans to study safety in a larger population.
Future Plans: Dr. Kenney revealed intentions to add an E7 cohort for further safety and effectiveness studies before moving to a randomized Phase 2a trial next year, comparing PROC patients at higher doses against standard care.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
